Skip to content

Released May 16, 2022, after the close

10-Q filed May 16, 2022, 46 days after period end · 0001193125-22-151851

Q1 2022 · 10-Q
Revenue—
Net Income-$9.13MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.23N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$9,206,000N/M
Operating Cash Flow-$8,299,000N/M
Free Cash Flowderived-$8,308,000—

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021
Net Income-$9.13M-$27.00M
EPS Diluted-$0.23-$64.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR